MARKET

LEXX

LEXX

Lexaria Bioscience Corp
NASDAQ
0.7000
+0.0212
+3.12%
Closed 16:00 03/13 EDT
OPEN
0.6652
PREV CLOSE
0.6788
HIGH
0.7220
LOW
0.6512
VOLUME
82.89K
TURNOVER
--
52 WEEK HIGH
1.896
52 WEEK LOW
0.4600
MARKET CAP
17.42M
P/E (TTM)
-1.2189
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LEXX last week (0302-0306)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 6d ago
Lexaria Launches 2026 R&D Push to Advance GLP-1 and Cannabidiol Drug Delivery
TipRanks · 03/04 15:37
Lexaria Bioscience announces 2026 R&D plans
TipRanks · 03/04 14:39
Lexaria launches 2026 GLP-1 clinical study GLP-1-H26-7
Reuters · 03/04 14:31
Lexaria Bioscience Launches 2026 R&D Program With Human And Animal GLP-1 Studies To Expand Drug Delivery IP And Business Opportunities
Benzinga · 03/04 14:28
Lexaria Bioscience Sets 2026 R&D Program With Planned Semaglutide Human Trial and Two GLP-1 Animal Studies to Evaluate New Oral Formulations and Support IP and Partnership Goals
Reuters · 03/04 14:25
Weekly Report: what happened at LEXX last week (0223-0227)?
Weekly Report · 03/02 09:08
More
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

Webull offers Lexaria Bioscience Corp stock information, including NASDAQ: LEXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEXX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEXX stock methods without spending real money on the virtual paper trading platform.